share_log

10-Q: Q2 2024 Earnings Report

10-Q: Q2 2024 Earnings Report

10-Q：2024财年二季报
美股SEC公告 ·  2024/08/07 03:12

Moomoo AI 已提取核心信息

BeiGene reported strong Q2 2024 financial results with total revenue increasing 56% year-over-year to $929.2 million, driven by robust global BRUKINSA sales growth of 107% to $637.4 million. Product revenue grew 66% to $921.1 million, while collaboration revenue was $8.0 million. The company reduced GAAP operating loss by 66% to $107.2 million and achieved positive adjusted operating income of $48.5 million.U.S. sales of BRUKINSA surged 114% to $479.4 million as it gained share in treatment-naive CLL and emerged as BTK inhibitor class leader in new patient starts. European sales grew 209% to $81.4 million with increased market penetration across major markets. China sales of tislelizumab increased 6% to $158.3 million, while Amgen in-licensed product sales in China rose 82% to $90.1 million.Gross margin improved to 85.0% from 82.7% in Q2 2023 due to higher BRUKINSA sales mix. Operating expenses increased 10% to $898.2 million, reflecting continued investment in commercial expansion and R&D. The company maintained strong liquidity with $2.6 billion in cash and investments as of June 30, 2024, positioning it well for continued global growth.
BeiGene reported strong Q2 2024 financial results with total revenue increasing 56% year-over-year to $929.2 million, driven by robust global BRUKINSA sales growth of 107% to $637.4 million. Product revenue grew 66% to $921.1 million, while collaboration revenue was $8.0 million. The company reduced GAAP operating loss by 66% to $107.2 million and achieved positive adjusted operating income of $48.5 million.U.S. sales of BRUKINSA surged 114% to $479.4 million as it gained share in treatment-naive CLL and emerged as BTK inhibitor class leader in new patient starts. European sales grew 209% to $81.4 million with increased market penetration across major markets. China sales of tislelizumab increased 6% to $158.3 million, while Amgen in-licensed product sales in China rose 82% to $90.1 million.Gross margin improved to 85.0% from 82.7% in Q2 2023 due to higher BRUKINSA sales mix. Operating expenses increased 10% to $898.2 million, reflecting continued investment in commercial expansion and R&D. The company maintained strong liquidity with $2.6 billion in cash and investments as of June 30, 2024, positioning it well for continued global growth.
百济神州公布了2024年第二季度强劲的财务业绩，总营业收入同比增长56%，达到92920万美元，这得益于全球BRUKINSA销售增长107%，达到63740万美元。产品收入增长66%，达到92110万美元，而合作收入为800万美元。公司将GAAP营业亏损减少了66%，至10720万美元，并实现了4850万美元的正调整营业收入。BRUKINSA在美国的销售激增114%，达到47940万美元，因为它在未治疗的CLL患者中获得了市场份额，并成为新的患者使用的BTk抑制剂类领导者。欧洲销售增长了209%，达到8140万美元，主要市场的市场渗透率不断提高。中国的tislelizumab销售同比增长6%，...展开全部
百济神州公布了2024年第二季度强劲的财务业绩，总营业收入同比增长56%，达到92920万美元，这得益于全球BRUKINSA销售增长107%，达到63740万美元。产品收入增长66%，达到92110万美元，而合作收入为800万美元。公司将GAAP营业亏损减少了66%，至10720万美元，并实现了4850万美元的正调整营业收入。BRUKINSA在美国的销售激增114%，达到47940万美元，因为它在未治疗的CLL患者中获得了市场份额，并成为新的患者使用的BTk抑制剂类领导者。欧洲销售增长了209%，达到8140万美元，主要市场的市场渗透率不断提高。中国的tislelizumab销售同比增长6%，达到15830万美元，而安进在中国的产品销售增长82%，达到9010万美元。毛利率从2023年第二季度的82.7%提高至85.0%，这得益于BRUKINSA销售组合的提升。营业费用增加10%，达到89820万美元，反映出公司在商业扩张和研发上的持续投资。到2024年6月30日，公司保持强劲的流动性，现金和投资达到26亿，为持续的全球增长奠定了良好的基础。

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

独立文件6  查看翻译

独立文件7  查看翻译

独立文件8  查看翻译

独立文件9  查看翻译

独立文件10  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间